261 related articles for article (PubMed ID: 34289822)
1. Disparities in risk perception and low harm reduction services awareness, access, and utilization among young people with newly reported hepatitis C infections in California, 2018.
Ohringer AR; Serota DP; McLean RL; Stockman LJ; Watt JP
BMC Public Health; 2021 Jul; 21(1):1435. PubMed ID: 34289822
[TBL] [Abstract][Full Text] [Related]
2. Prescription opioid injection among young people who inject drugs in New York City: a mixed-methods description and associations with hepatitis C virus infection and overdose.
Mateu-Gelabert P; Guarino H; Zibbell JE; Teubl J; Fong C; Goodbody E; Edlin B; Salvati C; Friedman SR
Harm Reduct J; 2020 Mar; 17(1):22. PubMed ID: 32228700
[TBL] [Abstract][Full Text] [Related]
3. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
[TBL] [Abstract][Full Text] [Related]
4. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
[TBL] [Abstract][Full Text] [Related]
5. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
[TBL] [Abstract][Full Text] [Related]
6. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
7. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs.
Prouté M; Le Coeur S; Tiv MH; Dub T; Jongpaijitsakul P; Ratnamhin A; Angkurawaranon C; Aramrattana A; Lallemant M
BMC Public Health; 2020 Sep; 20(1):1450. PubMed ID: 32972359
[TBL] [Abstract][Full Text] [Related]
8. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.
Auriacombe M; Roux P; Briand Madrid L; Kirchherr S; Kervran C; Chauvin C; Gutowski M; Denis C; Carrieri MP; Lalanne L; Jauffret-Roustide M;
BMJ Open; 2019 Feb; 9(2):e023683. PubMed ID: 30796121
[TBL] [Abstract][Full Text] [Related]
9. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
[TBL] [Abstract][Full Text] [Related]
10. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants.
Folch C; Saludes V; Reyes-Ureña J; Antuori A; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2021 Apr; 90():103057. PubMed ID: 33310634
[TBL] [Abstract][Full Text] [Related]
11. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
Bruggmann P; Grebely J
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
[TBL] [Abstract][Full Text] [Related]
12. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
14. Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia.
Baker LS; Smith W; Gulley T; Tomann MM
J Community Health; 2020 Apr; 45(2):239-244. PubMed ID: 31502098
[TBL] [Abstract][Full Text] [Related]
15. Access to harm reduction programs among persons who inject drugs: findings from a respondent-driven sampling survey in Tehran, Iran.
Rahnama R; Mohraz M; Mirzazadeh A; Rutherford G; McFarland W; Akbari G; Malekinejad M
Int J Drug Policy; 2014 Jul; 25(4):717-23. PubMed ID: 24974367
[TBL] [Abstract][Full Text] [Related]
16. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015.
Graham S; Maher L; Wand H; Doyle M; Iversen J
Int J Drug Policy; 2017 Sep; 47():69-76. PubMed ID: 28735774
[TBL] [Abstract][Full Text] [Related]
17. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
18. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL.
Bartholomew TS; Onugha J; Bullock C; Scaramutti C; Patel H; Forrest DW; Feaster DJ; Tookes HE
Harm Reduct J; 2020 Jun; 17(1):40. PubMed ID: 32522201
[TBL] [Abstract][Full Text] [Related]
19. Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection.
Artenie AA; Hickman M; Vickerman P; Stone J; Grebely J; Bruneau J
Int J Drug Policy; 2021 Oct; 96():103419. PubMed ID: 34452807
[TBL] [Abstract][Full Text] [Related]
20. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
